Rasio rega marang prakiraan pendapatan biogen.com (BIIB)
Biogen Inc. (BIIB) management is restoring investor confidence following controversial market launches. The forward price-to-sales valuation on the GURU.Markets chart visualizes the results of this strategy, where 0.50 represents the latest metric reading. The growth of the biosimilars portfolio reduces patent risks, although geopolitical fragmentation complicates international biomaterial logistics and the conduct of global clinical trials.
Biogen Idec (BIIB) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Total Utang marang Modal Biogen Inc.|BIIB - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Biogen Inc.|BIIB - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Biogen Idec|BIIB - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Biogen|Likuiditas cepet biogen.com
- rincian asil keuangan lan kelipatan valuasi:
BIIB - Bathi perusahaan|Proyeksi bathi mangsa ngarep Biogen Inc.|BIIB - Kapitalisasi marang bathi|Prakiraan rega marang bathi Biogen Corp|BIIB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Biogen Idec|BIIB - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Biogen|BIIB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan biogen.com|BIIB - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Biogen Inc.
- data dodolan lan asil:
Analisis komprehensif perusahaan:Biogen BIIB
To build a defensive portfolio, fundamental screening requires an assessment of market value relative to expected earnings. This metric is calculated as the ratio of the current market capitalization of Biogen Inc. (BIIB) to projected revenue for the following year, excluding quarterly report volatility. Extensive outsourcing of clinical trials and logistics optimizes costs, making the forward price-to-sales ratio a key indicator of capital management efficiency.
Analisis perusahaan pesaing
Multiplikator Forward P/S NBIX (Neurocrine Biosciences, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Regencell Bioscience Ltd (RGC)|AXSM - Rasio rega marang prakiraan pendapatan|ACAD (ACADIA Corp) - Kapitalisasi marang prakiraan pendapatan|XENE: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan vikingtherapeutics.com|Multiplikator forward rega marang pendapatan SUPN|Catalyst Pharma (CPRX) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S DNLI|Rasio rega marang prakiraan pendapatan HRMY (Harmony Corp)|Multiplikator Forward P/S BHVN (Biohaven Ltd.)|Rasio kapitalisasi marang dodolan sing dikarepake amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Praxis Precision Medicines Inc PRAX|AVXL: Multiplikator Forward P/S|CBLL (CeriBell EEG) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Prothena Biosciences|Kapitalisasi marang prakiraan pendapatan ALEC (Alector Therapeutics)|Multiplikator Forward P/S ANNX|OMER - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Neurogene Corp - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S AC Immune Inc ACIU|VYGR - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan NMRA (neumoratx.com)|Scilex (SCLX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tevogen Bio Holdings Inc. (TVGN)|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan CGTX|Multiplikator Forward P/S IKT|Rasio kapitalisasi marang dodolan sing dikarepake cassavasciences.com|Rasio rega marang prakiraan pendapatan Assertio ASRT|Coya Therapeutics Inc (COYA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VistaGen Therapeutics Inc - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Ovid Therapeutics Inc. (OVID)|ABOS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep cervomed.com (CRVO)|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Ltd.|Kapitalisasi marang prakiraan pendapatan CLNN (Clene Nanomedicine)|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc.)|JUNS (Jupiter Neurosciences, Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S RLMD (Relmada Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake annovisbio.com (ANVS)|GRCE - Rasio rega marang prakiraan pendapatan|AIFF (Firefly Neuroscience, Inc.) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NeuroSense Therapeutics Ltd.|Multiplikator forward rega marang pendapatan RVPH|MetaVia, Inc. (MTVA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S NRXS|Rasio rega marang prakiraan pendapatan HSDT (heliusmedical.com)|Multiplikator Forward P/S PASG (Passage Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake athira.com ATHA|ADXN: Multiplikator Forward P/S|ALZN (Alzamend Neuro) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|Kapitalisasi marang prakiraan pendapatan PTIX (Protagenic)|Multiplikator Forward P/S KTTA|CRGT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Avenue Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Brainstorm Cell Therapeutics Inc. BCLI|CARA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CHRO (Chromocell)|eliemtx.com (ELYM) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan MRNS|Multiplikator Forward P/S NKGN|Rasio kapitalisasi marang dodolan sing dikarepake NeuroBo Pharma|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|synaptogen.com (SNPX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Trevena - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Vigil Neuroscience (VIGL)|WENA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cerevel Corp (CERE)
